Effects of the combination of a dipeptidyl peptidase IV inhibitor and an insulin secretagogue on glucose and insulin levels in mice and rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 2, 2007, Pages 738-746

  Yamazaki, Kazuto ^a   Yasuda, Nobuyuki ^a   Inoue, Takashi ^a   Yamamoto, Eiichi ^a   Sugaya, Yukiko ^a   Nagakura, Tadashi ^a   Shinoda, Masanobu ^a   Clark, Richard ^a   Saeki, Takao ^a   Tanaka, Isao ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 BUT 2 YNYL 5 METHYL 2 PIPERAZIN 1 YL 3,5 DIHYDRO 4H IMIDAZO[4,5 D]PYRIDAZIN 4 ONE TOSYLATE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; E 3024; GLIBENCLAMIDE; GLUCOSE; INSULIN; NATEGLINIDE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; CYCLOHEXANES; GLUCAGON-LIKE PEPTIDE 1; GLYBURIDE; IMIDAZOLES; INSULIN; MALE; MICE; MICE, INBRED C57BL; PHENYLALANINE; PROTEASE INHIBITORS; PYRIDAZINES; RATS; RATS, WISTAR; TOSYL COMPOUNDS;

EID: 33846411047     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.112011     Document Type: Article

References (30)

1. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP, IV, Boyd AE, III, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J, and Nelson DA (1995) Cloning of the β cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science (Wash DC) 268:423-426.
2. Ahrén B, Pacini G, Foley JE, and Schweizer A (2005) Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28:1936-1940.
3. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P-A, Sandqvist M, Båvenholm P, Efendic S, Eriksson JW, et al. (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875.
4. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, and Wang PR (2005) Acute and chronic effects of the incretin enhancer vildagliptin in insulin resistant rats. J Pharmacol Exp Ther 315:688-695.
5. Ceriello A (2000) The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 16:125-132.
6. Deacon CF, Ahrén B, and Holst JJ (2004) Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes. Expert Opin Investig Drugs 13:1091-1102.
7. Demuth H-U, McIntosh CH, and Pederson RA (2005) Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 1751:33-44.
8. Ehses JA, Pelech SL, Pederson RA, and McIntosh CHS (2002) Glucose-dependent insulintropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 277:37088-37097.
9. 3H] glibenclamide. Biochem Pharmacol 52:407-411.
10. Gromada J, Brock B, Schmitz O, and Rorsman P (2004) Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 95:252-262.
11. Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, and Efendic S (1996) Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 19:857-863.
12. Gutniak MK, Linde B, Holst JJ, and Efendic S (1994) Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039-1044.
13. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, and Drucker DJ (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53:1326-1335.
14. Ikenoue T, Akiyoshi M, Fujitani S, Okazaki K, Kondo N, and Maki T (1997) Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). Br J Pharmacol 120:137-145.
15. Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, Yano H, and Seino S (2001) Critical role of cAMP-GEFII·Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276:46046-46053.
16. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, et al. (2005) (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl] -1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151.
17. Krentz AJ and Bailey CJ (2005) Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs 65:385-411.
18. Monnier L (2000) Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Investig 30 (Suppl 2):3-11.
19. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, and Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744.
20. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, and Demuth H-U (1998) Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47:1253-1258.
21. Reimer MK, Holst JJ, and Ahrén B (2002) Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717-727.
22. Sorbera LA, Revel L, and Castañer L (2001) P32/98. Antidiabetic dipeptidyl peptidase IV inhibitor. Drugs Future 26:859-864.
23. Takasaki K, Nakajima T, Ueno K, Nomoto Y, and Higo K (2004) Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats. J Pharmacol Sci 95:291-293.
24. 1c level. Diabetes Care 23:1830-1834.
25. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853.
26. Van Gaal LF and De Leeuw IH (2003) Rational and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 46 (Suppl 1):M44-M50.
27. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, and Hughes TE (2003) 1-[[(3-Hydroxy-1-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789.
28. Winzell MS and Ahrén B (2004) The high-fat diet-fed mouse. A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53 (Suppl 3):S215-S219.
29. Yasuda N, Nagakura T, Inoue T, Yamazaki K, Katsutani N, Takenaka O, Clark R, Matsuura F, Emori E, Yoshikawa S, et al. (2006) E3024, 3-but-2-ynyl-5- methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d] pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase IV inhibitor. Eur J Pharmacol 548:181-187.
30. Yip RG and Wolfe MM (2000) GIP biology and fat metabolism. Life Sci 66:91-103.